Prostate cancer cells derived from transgenic mice with adenocarcinoma of the prostate (TRAMP cells) were treated with the HMG-CoA reductase inhibitor, lovastatin. This caused inactivation of the small GTPase RhoA, actin stress ®ber disassembly, cell rounding, growth arrest in the G1 phase of the cell cycle, cell detachment and apoptosis. Addition of geranylgeraniol (GGOL) in the presence of lovastatin, to stimulate protein geranylgeranylation, prevented lovastatin's eects. That is, RhoA was activated, actin stress ®bers were assembled, the cells assumed a¯at morphology and cell growth resumed. The following observations support an essential role for RhoA in TRAMP cell growth: (1) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein displayed few actin stress ®bers and grew at a slower rate than controls (35 h doubling time for cells expressing RhoA (T19N) vs 20 h for untransfected cells); (2) TRAMP cells expressing constitutively active RhoA (Q63L) mutant protein displayed a contractile phenotype and grew faster than controls (13 h doubling time). Interestingly, addition of farnesol (FOL) with lovastatin, to stimulate protein farnesylation, prevented lovastatin-induced cell rounding, cell detachment and apoptosis, and stimulated cell spreading to a spindle shaped morphology. However, RhoA remained inactive and growth arrest persisted. The morphological eects of FOL addition were prevented in TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein. Thus, it appears that H-Ras is capable of inducing cell spreading, but incapable of supporting cell proliferation, in the absence of geranylgeranylated proteins like RhoA.
Introduction
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitor, lovastatin, has been extensively studied as a possible chemotherapeutic agent in the treatment of cancer. At high concentrations, lovastatin arrests cell growth and induces apoptosis (Jones et al., 1994; Newman et al., 1994; Ghosh et al., 1997) . Lovastatin prevents the conversion of HMG CoA to mevalonate, and thereby inhibits the synthesis of the other products of the mevalonate pathway. This includes geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) (Grunler et al., 1994) , which modify and target small GTPases, including Ras and Rho, to their site of action (Sinensky and Lutz, 1992; Bourne et al., 1990) . The small GTPases act as molecular switches, tracking from a membrane-bound (active) GTP-bound state, to a cytosolic (inactive) GDP-bound state (Bourne et al., 1990) . Lovastatin, by inhibiting the synthesis of GGPP and FPP, prevents the activation of these small GTPases. Thus, it aects multiple cellular functions by interfering with basic cell signaling pathways necessary for cell growth and survival. The geranylgeranylated proteins of the Rho subfamily, including RhoA, Rac1 and Cdc42Hs, are involved in cell shape regulation and actin ®lament assembly (Hall, 1998; Takai et al., 1995) . Inactivation of these proteins with lovastatin causes cell rounding and actin ®lament disassembly (Fenton et al., 1992) . The farnesylated Ras proteins, on the other hand, are associated with cell proliferation (Khosravi-Far and Der, 1994; Prendergast and Gibbs, 1993; Pronk and Bos, 1994) . It has been shown that activation of Rho proteins are also necessary for cell proliferation (Hirai et al., 1997; Hill et al., 1995; Joneson and Bar-Sagi, 1998; Olson et al., 1998) . These proteins have also been found to activate the JNK/SAPK signaling pathway in a celltype speci®c manner (Zhang et al., 1995; Coso et al., 1995; Teramoto et al., 1996) .
In this report, we used a prostatic tumor cell line derived from a transgenic mouse with adenocarcinoma of the prostate (the TRAMP mouse) to study the role of the small GTPase RhoA in cell growth and morphology. The transgenic mouse model for prostate cancer was established by using a prostate-speci®c transgene expression system based on the regulatory elements of the rat probascin-encoding gene Greenberg et al., 1995) . Mice expressing high levels of the transgene displayed progressive forms of prostatic disease that histologically resembled human prostate cancer, ranging from intraepithelial hyperplasia to large malignant neoplastic nodules. Cell lines established from a tumor in these mice express the androgen receptor but no longer express the SV40 large T-antigen (Foster et al., 1997) . This eliminates complications arising from the eects of SV40 T antigen on the retinoblastoma protein (pRb) and p53 which are known to interact with it. We used one cell line established from these tumors (TRAMP cells) to study the mechanism of lovastatin-induced cell rounding and growth arrest. We found that while cell spreading could be restored by the addition of both geranylgeraniol (GGOL) or farnesol (FOL) to lovastatin-treated cells, only GGOL restored cell proliferation, thus allowing us to separate the eects of the isoprenoids on these two events. We also determined the role of H-Ras and RhoA in TRAMP cell morphology and growth by transfecting cells with dominant-negative or constitutively activated mutant genes of these proteins to identify the major regulators of TRAMP cell morphology and proliferation. We determined that TRAMP cells require active RhoA, but not Rac1, for cell growth, and that H-Ras is incapable of stimulating cell growth in the absence of active RhoA. Our data are consistent with the hypothesis that RhoA exerts its eect by stimulating actin stress ®ber development.
Results

GGOL, but not FOL, rescues TRAMP cells from the antiproliferative eects of lovastatin
We studied the role of isoprenylation in the growth and morphology of TRAMP cells by treating the cells with lovastatin, which prevents isoprenoid synthesis. Untreated TRAMP cells were¯at and well spread with actin stress ®bers ( Figure 1a ) but after 24 h of lovastatin treatment (10 mM), the cells were round and actin stress ®bers were disassembled (Figure 1b) . The role of geranylgeranylated or farnesylated proteins was studied by treating cells with GGOL or FOL in the presence of lovastatin. Inclusion of GGOL (10 mM) or FOL (10 mM) with lovastatin prevented cell rounding. Cells treated with lovastatin in the presence of GGOL were well spread like the control cells ( Figure  1c ), but the cells plated with lovastatin in the presence of FOL were spindle-shaped (Figure 1d) . Similarly, TRAMP cells treated with lovastatin for 24 ± 48 h respread after addition of GGOL or FOL; however, cells treated with lovastatin for longer periods of time than 48 h failed to recover after GGOL or FOL addition. Lovastatin treatment also caused TRAMP cells to arrest at the G1 phase of the cell cycle and inhibited cell proliferation (Table 1 and Figure 2) . By 48 h of lovastatin treatment, there were very few cells Figure 1 Fluorescence photomicrographs showing the eect of 24 h of treatment with 10 mM lovastatin with or without GGOL or FOL on TRAMP cell morphology and actin stress ®ber assembly as detected by rhodamine phalloidin staining: (a) untreated cells were¯at and displayed abundant actin stress ®bers while (b) lovastatin treated cells were round and displayed no actin stress ®ber assembly. (c) Inclusion of 10 mM GGOL with lovastatin largely prevented lovastatin's eects. The cells respread and displayed actin stress ®bers. Although the cells also respread by including FOL (10 mM) with lovastatin, they assumed a spindle shape. (d) Bar, 50 mm in the S phase of the cell cycle (Table 1) . Despite the ability of the cells to respread with both isoprenoids, only GGOL addition promoted G1 to S phase cell cycle progression and proliferation (Table 1 and Figure  2 ). Concentrations of lovastatin less than 5 mM did not aect cell morphology or cell growth.
GGOL, but not FOL, translocates RhoA from the cytosol (where it is inactive) to the membrane (where it is active) in lovastatin-treated cells
Microinjection experiments have determined that
RhoA is the small GTPase that mediates the assembly of actin stress ®bers . In Activation of the small GTPase RhoA is necessary for TRAMP cell proliferation
To further investigate the role of RhoA in TRAMP cell proliferation, we stably transfected TRAMP cells with constructs containing the genes encoding for Figure 2 Eect of lovastatin on cell proliferation. TRAMP cells were plated in duplicate in 35 mm dishes at a concentration of 10 4 cells/cm 2 either untreated or in the presence of 10 mM lovastatin with or without 10 mM GGOL or 10 mM FOL. At the end of 1, 2, and 3 days, the number of attached and¯oating cells were counted using a hemocytometer under a light microscope. constitutively activated rhoA (Q63L) or dominantnegative rhoA (T19N) (Figure 5a ). Cells expressing constitutively active RhoA (Q63L) mutant protein grew at a faster rate than untransfected TRAMP cells due to a shortening of the G1 phase of the cell cycle (43% of asynchronous cells were in the G1 phase of the cell cycle vs 60% for controls). On the other hand, cells expressing dominant-negative RhoA (T19N) mutant protein had a much slower proliferation rate due to a longer G1 phase (85% of asynchronous cells in G1) ( Table 2 Another small geranylgeranylated GTPase, Rac1, has been implicated in the assembly of the actin cytoskeleton leading to cell proliferation (Joneson et al., 1996; Lamarche et al., 1996) and, thus, could also be a mediator of TRAMP cell growth. In contrast to TRAMP cells that express dominantnegative RhoA (T19N) (Figure 6b) ). However,¯ow cytometry revealed that DNA synthesis was increased by the expression of constitutively activated Rac1 (Q61L) mutant protein (Table 2 ). This was most likely due to activation of RhoA, as RhoA has been shown to act downstream of activated Rac1 (Symons, 1995; Chant and Stowers, 1995) . In further support of a role for RhoA activation in TRAMP cell growth, cells expressing dominant-negative Rac1 (T17N) mutant protein continued to proliferate after treatment with lovastatin and GGOL, while cells expressing dominant-negative RhoA (T19N) mutant protein remained growth arrested under similar conditions (Table 3 and Figure 6 ).
Cell spreading in TRAMP cells can occur in the absence of activated RhoA
RhoA is a well-known regulator of actin stress ®ber assembly (Hall, 1998; Takai et al., 1995; . The degree of actin stress ®ber assembly was assessed microscopically after staining cells with rhodamine phalloidin (Figure 7 ) and quantitated by¯ow cytometry (Figure 8 ). Expression of constitutively activated RhoA (Q63L) mutant protein caused enhanced actin stress ®ber assembly (Figures 7 and 8) . Interestingly, greater than 75% of the cells displayed a contracted, transformed phenotype ( Figure 7 , bottom panel). TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein, on the other hand, displayed fewer actin stress ®bers, despite beinḡ at and well spread (Figures 7, middle panel, and 8). Both forward and right angle light scattering were used to assess cell size. Cells expressing constitutively activated RhoA (Q63L) mutant protein were smaller than untransfected cells, re¯ecting the observed smaller, contractile phenotype, while those expressing dominant-negative RhoA (T19N) mutant protein were found to be larger than untransfected controls or cells expressing constitutively active RhoA (Q63L) (Figure 9 ). The cell spreading observed in TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein as well as in untransfected TRAMP cells treated with lovastatin and FOL, where RhoA is inactive ( Figure  3 ), indicate that RhoA activation, although necessary for actin stress ®ber assembly, is not necessary for cell spreading. The¯at and well-spread 
FOL's eects on lovastatin-treated TRAMP cells are mediated by H-Ras
The farnesylated Ras proteins (H-Ras, K-Ras and NRas) stimulate cell proliferation by activating the Raf/ MAPK pathway, leading to gene transcription (Khosravi-Far and Der, 1994; Prendergast and Gibbs, 1993; Pronk and Bos, 1994) . Recent studies have shown that while K-Ras and N-Ras can be geranylgeranylated in the absence of farnesylation, H-Ras cannot (Whyte et al., 1997; Rowell et al., 1997) . Thus, H-Ras is only activated in the presence of FOL and not in the presence of GGOL, making it a strong candidate for mediating FOL-induced spreading of lovastatin-treated TRAMP cells. We stably transfected TRAMP cells with a vector containing the gene for dominantnegative H-ras (T17N) which has a dexamethasoneinducible promoter. Transfected cells showed high expression of the mutant protein (Figure 5c ). In the absence of dexamethasone (50 mM), transfected TRAMP cells were spindle shaped for as long as 72 h after lovastatin and FOL treatment. Treatment with dexamethasone (50 mM), to induce transcription of the gene encoding for dominant-negative H-ras (T17N), caused the cells to round and detach after treatment with lovastatin and FOL (Figures 10 and  11 ). This eect on cell shape and adhesion was not due to dexamethasone because untransfected TRAMP cells remained spindle shaped over the same period of time when treated with lovastatin and FOL in the presence of 50 mM dexamethasone. Expression of dominantnegative H-Ras (T17N) mutant protein caused a decline in the number of attached cells which was re¯ected in an increase in¯oating cells (Figure 11b Quantitation of the amount of actin stress ®bers present in cells by rhodamine phalloidin staining. Untransfected TRAMP cells or those expressing mutated RhoA proteins were plated at a concentration of 500 000 cells/10 cm dish. Twentyfour hours after plating, the cells were ®xed and stained with rhodamine phalloidin. Flow cytometry of 20 000 cells revealed that the cells expressing dominant-negative RhoA (T19N) mutant protein had signi®cantly less actin stress ®bers compared to untransfected cells or those expressing constitutively active RhoA (Q63L) mutant protein, con®rming our earlier observations proliferate (Figure 11a) . The above data suggested that FOL's eects on lovastatin treated cells, namely spreading to the spindle shape, as well as prevention of cell detachment and apoptosis, were mediated by HRas and that H-Ras is unable to support cell proliferation in the absence of geranylgeranylated proteins like RhoA.
Discussion
Lovastatin treatment caused TRAMP cells to round up and disassemble actin stress ®bers, and also arrested cell growth at the G1 phase of the cell cycle. These eects of lovastatin were reversed by GGOL. While FOL caused cell spreading to a spindle-shaped morphology, it did not inhibit lovastatin-induced growth arrest. Experiments with TRAMP cells expressing mutant Ras and Rho proteins showed that the geranylgeranylated small GTPase, RhoA, mediated TRAMP cell growth. H-Ras was found to mediate the spindle-shaped morphology observed after treatment of TRAMP cells with lovastatin in the presence of FOL. We found a direct correlation between RhoAstimulated growth and actin stress ®ber assembly. This is supported by the observation that: (1) addition of GGOL to lovastatin-treated cells resulted in actin stress ®ber assembly; (2) TRAMP cells expressing constitutively active RhoA (Q63L) mutant protein grew at a greater rate than untransfected TRAMP cells, displayed abundant arrays of actin stress ®bers and displayed a contractile phenotype; and (3) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein contained fewer actin stress ®bers and grew more slowly than either untransfected TRAMP cells or cells expressing constitutively active RhoA (Q63L) mutant protein. This suggests that RhoA exerts its eect on TRAMP cell growth through the stimulation of actin stress ®ber assembly.
In addition to their well characterized roles as inducers of cell proliferation, Ras proteins have rapid and profound eects on the actin cytoskeleton (Nobes and Hall, 1995; Bar-Sagi and Feramisco, 1986; Rodriguez-Viciana et al., 1997) . Most importantly, both pathways (i.e. cell growth and cytoskeletal remodeling) must be activated for normal cell growth as well as for establishing and maintaining the transformed phenotype Prendergast et al., 1995; Qiu et al., 1995a,b) . When activated Ras is microinjected into ®broblasts, there is induction of membrane ruing and assembly of actin stress ®bers (Bar- Sagi and Feramisco, 1986) . Microinjection experiments revealed that Rho proteins Figure 9 Estimation of cell size. Untransfected TRAMP cells, or those expressing constitutively active or dominant-negative RhoA mutant proteins, were plated at a concentration of 10 6 cells/dish on 10 cm tissue culture dishes, and trypsinized 24 h after plating. The cell suspension was analysed by forward and right angle scattering on a¯uorescence activated cell sorter to measure cell size. Note that TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein were larger than those expressing constitutively activated RhoA (Q63L) mutant protein or untransfected TRAMP cells, as detected by a shift to higher values in the light scattering collected from these cells Figure 10 Eect of H-Ras on TRAMP cell spreading in the presence of lovastatin and FOL. TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein were treated for 48 h with lovastatin and FOL. (a) In the absence of dexamethasone (H-Ras would be active), the cells spread to a spindle shape when treated with 10 mM lovastatin plus 10 mM FOL. (b) In the presence of dexamethasone, dominant-negative H-ras (T17N) is induced and the cells remained round (Cdc42, Rac, and Rho) act in concert and function in a cascade where Ras activates Rac which results in membrane ruing followed by activation of Rhomediated actin stress ®ber development Nobes and Hall, 1995; Bar-Sagi and Feramisco, 1986) . Thus, by controlling the activation state of Rac and Rho, Ras can regulate the cell cytoskeleton as well as stimulate cell growth. In the absence of Rac or Rho activation (for example, in cells treated with lovastatin and FOL), Ras could still stimulate cell spreading and actin ®lament assembly. This indicates the activation of an alternate pathway not involving Rac or Rho. It has been previously reported that Ras activates PI 3-kinase (Rodriguez-Viciana et al., 1997) whose products, PI(3,4)P2 and PI(3,4,5)P3 induce F-actin assembly (Derman et al., 1997; Yao et al., 1995) . In TRAMP cells, Ras may be inducing cell spreading via PI 3-kinase; but the F-actin produced may not be organized into stress ®bers involving bound myosin.
Previously, it was reported in endothelial cells, that ā at, spread cellular morphology permitted DNA synthesis while round cells did not proliferate and underwent apoptosis . Shapes in between¯at and round, for example, the spindle shaped cells seen on treatment of TRAMP cells with lovastatin and FOL, may prevent apoptosis, but may not be conducive to proliferation. However, our results showed that the degree of cell spreading was not the determinant of cell cycle progression, but, rather, activation of RhoA and actin stress ®ber development were necessary for cell division. In support of this argument, TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein were well spread and larger than cells expressing constitutively active RhoA (Q63L) mutant protein, despite growing considerably slower than cells expressing constitutively active RhoA (Q63L) mutant protein.
Stress ®bers are contractile bundles of ®lamentous (F)-actin and myosin II that mediate cell tension development, cell adhesion, cell migration, and cell locomotion, (Chrzanowska-Wodnika and Burridge, 1996; Kreisberg et al., 1985 Kreisberg et al., , 1997 Bragina et al., 1976; Spooner et al., 1982) . Two downstream targets of RhoA activation promote actin stress ®ber formation: (1) activation of phosphatidylinositol 5-kinase (Chong et al., 1994) whose lipid product phosphatidylinositol 3,4,5-bisphosphate activates a-actinin, an actin binding protein required for the proper assembly of actin stress ®bers (Fukami et al., 1992) ; and (2) activation of Rho kinase which phosphorylates myosin light chain allowing binding to F-actin and the development of the contractile bundle (Amano et al., 1997) . Actin stress ®bers connect at one end to the plasma membrane at specialized sites called focal contacts where the external surface of the plasma membrane is attached to the substratum. At the other end, actin stress ®bers insert into a second focal contact or into the intermediate ®lamentous network surrounding the nucleus. In cultured cells, stress ®bers serve to dissipate tension created by shear forces across cells to areas of cell contact, and they also provide a mechanical link between the cell surface and nucleus. Indeed, increased mechanical strain has been shown to stimulate DNA synthesis in cultured smooth muscle cells (Maniotis et al., 1997; Wilson et al., 1995) , providing a link between the cytoskeleton and cell proliferation. We propose the cytoskeleton signals the nucleus to alter expression of genes important for cell cycle progression. In this regard, Zhu et al. (1996) reported that in order for cell cycle progression to occur, the actin cytoskeleton must be assembled, and Noguchi et al. (1998) recently reported that activation of RhoA and not Ras is necessary for G1 to S transition in rat thyroid cells. Our results imply that it is the activation of RhoA with the development of actin stress ®bers and intracellular tension that signals cell cycle progression. If the cytoskeleton is disassembled prior to a cell reaching the restriction point, growth is arrested (Zhu et al., 1996) . Other reports have indicated that RhoA stimulates cell cycle progression through inactivation of the cyclin dependent kinase inhibitors (CKIs) p27
Kip1 (Hirai et al., 1997) 
or p21
Cip1 (Olson et al., 1998) . Our results suggest that, activation of RhoA results in actin stress ®ber assembly, which would provide the signals leading to cell proliferation. These signals may be mediated by the CKIs p27
Kip1 and p21 Cip1 (Hirai et al., 1997; Olson et al., 1998) . Under conditions where RhoA might be expected to be active (e.g. in ras-transformed cells where constitutively active Ras protein would be expected to lead to constitutive active RhoA) there would be increased assembly of actin stress ®bers leading to the contractile phenotype often observed in transformed cells (Qiu et al., 1995a) . Indeed, TRAMP cells expressing constitutively active RhoA mutant protein also displayed a contractile phenotype. In support of this, Avraham and Weinberg (1989) reported that ampli®cation of the human rhoA gene in NIH3T3 cells resulted in cells that were tumorigenic in nude mice and suggested that this gene be considered a proto-oncogene.
Under conditions where farnesylated Ras proteins are active, but geranylgeranylated Rho and Rac proteins are not (treatment with lovastatin and FOL), the activation of the MAPK signaling pathway alone is not conducive to cell cycle progression. Thus, our data suggests that cell proliferation requires tension development created with the activation of RhoA through the assembly of actin stress ®bers. We are currently studying the details of this mechanism, and also the mechanism by which H-Ras induces TRAMP cell spreading to the spindle shaped morphology.
Materials and methods
Cell culture
Transgenic mouse prostate (TRAMP) cancer cells are a clonal derivative of the TRAMP-C2 line described by Foster et al. (1997) . This cell line expresses cytokeratin, and androgen receptor, but does not express E-cadherin or Tantigen oncoprotein. The cells were cultured in Dulbecco's Modi®ed Eagle Medium containing high glucose (Gibco± BRL, Life Technology, Grand Island, NY, USA) supplemented with 5% Fetal Bovine Serum (Gibco), 5% NuSerum (Collaborative Biomedical Products, Becton Dickinson Labware, Bedford, MA, USA), 5 mg/ml insulin (Sigma Biosciences, St Louis, MO, USA), 25 U/ml PenicillinStreptomycin (CellGro Mediatech) and 10 nM dihydrotestosterone (Sigma). . Cells were stably transfecting using lipofectamine reagent (Gibco±BRL, Life Technologies, Gaithersberg, MD, USA). Cells were transfected with 1 mg DNA and 100 ng of a vector containing the neomycin-resistant gene and 10 mg of lipofectamine per 100 mm dish. Cells expressing mutant proteins were selected by resistance to G-418. Transfected cultures were maintained in growth medium containing G-418 at 400 mg/ml (Mediatech, Inc., Herndon, VA, USA) to establish cell lines that stably express the mutant proteins. Transient transfections were performed similar to that described above for stable transfections, but without the neomycin-resistant vector. Experiments with the transiently transfected cells were performed 24 h after the transfection.
Pharmacological treatment
Lovastatin was a gift from Merck Research Laboratories, Rahway, NJ, USA and was prepared as described by Kita et al. (1980) . Brie¯y, lovastatin (90 mg) was dissolved in warm (558C) ethanol (1.8 ml) by dropwise addition of 0.6 N NaOH (0.9 ml) and 18 ml water. The solution was incubated 30 min at room temperature and the pH was adjusted to 7.4. The ®nal volume was increased to 22.5 ml to give a stock solution of 10 mM. TRAMP cells were treated for dierent time periods with 10 mM lovastatin in serum. All-trans-geranylgeraniol and all-trans-farnesol were purchased from Sigma Biosciences (St Louis, MO, USA), and dissolved in 95% ethanol (1 M), then diluted further in 45% w/v hydroxypropyl-b-cyclodextrin (Aldrich Chemical Co, Milwaukee, WI, USA) to a stock solution of 10 mM. Cells were treated with 10 mM GGOL or FOL.
Fluorescence microscopy TRAMP cells were grown on coverslips under required conditions and ®xed for 1 h in a modi®ed Zamboni ®xative (800 mg paraformaldehyde dissolved in 3 ml hot saturated picric acid by dropwise addition of 1 N NaOH, cooled, 180 mg NaCl added, and the volume adjusted to 20 ml with 50 mM Na Phosphate buer, pH 7.4). The ®xed cells were then permeabilized with 0.4% Triton X-100 in PBS for 2 min at room temperature, and incubated 20 min in 2 U/ml rhodamine phalloidin (Molecular Probes, Eugene, OR, USA). Observations were made under standard epifluorescence optics (Zeiss Inc, Thornwood, NJ, USA) or using a confocal microscope (Zeiss).
Growth curves
Cell growth was assessed approximately every 12 h over a period of 4 days. Cells were plated in duplicate in 35 mm dishes at a concentration of 0.5610 4 cells/dish, trypsinized and counted using a hemocytometer. Each point on the growth curve represents the mean of two dishes, each dish being counted three times. Doubling times were estimated by plotting the number of cells vs time for each cell line. The resulting curve was ®tted to the closest polynomial equation using Cricket Graph (Cricket Software, Malvern, PA, USA). The polynomial equation used for curve ®tting was then used to calculate the doubling time at three dierent time points and the mean value was assumed to represent the doubling time for that cell line. The number of¯oating cells were also counted in most cases.
Assessment of apoptosis
Apoptotic cells were identi®ed according to the following criteria: condensed and fragmented nuclei, cell blebbing and decrease in cell size (Oberhammer et al., 1993) .
Fluorescent staining Cells were stained with the DNA binding¯uorochrome Hoechst 33258 stain (Oberhammer et al., 1993) and nuclear morphology examined under a Zeiss epi¯uorescence photomicroscope (Zeiss Inc, Thornwood, NJ, USA).
Transmission electron microscopy Floating and attached cells were ®xed in 4% paraformaldehyde/1% glutaraldehyde for 30 min and processed for electron microscopy.
Flow cytometry
TRAMP cells were grown under desired conditions in 100 mm dishes at 500 000 cells/dish. Cells to be processed for¯ow cytometry were trypsinized, then pipetted o the surface in 2 ml cell growth medium, and spun down in a table top centrifuge. The medium was aspirated and the pellet washed once in PBS. The cells were then resuspended in 500 ml 70% ethanol, and incubated 30 min at 7208C. The cells were repelleted, and washed twice in 1% BSA/PBS. For staining for actin stress ®bers, the cells were resuspended in 300 ml Rhodamine Phalloidin solution prepared by diluting 10 ml of 200 U/ml Rhodamine Phalloidin (Molecular Probes, Eugene, OR, USA) in 1 ml PBS containing 20 ml of 20% Triton-100, and incubated overnight at 48C. For nuclear staining with propidium iodide, the cells were suspended in 150 ml PBS, 50 ml of 1 mg/ml RNAse A (Sigma) and 100 ml of 100 mg/ml propidium iodide (Sigma) and incubated overnight at 48C. Flow cytometry was conducted on FACStar Plus (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Cells were illuminated with 200 mW of 488 nm light produced by an argon ± ion laser. Fluorescence was read through a 575/26 nm (for rhodamine) or a 630/22 nm (for propidium iodide) band-pass ®lter. Data were collected on 20 000 cells as determined by forward and right angle light scatter and stored as frequency histograms; data used for cell cycle analysis was then analysed using MODFIT (Verity software, Topsham, ME, USA).
Measurement of cell size
Cells were trypsinized and then resuspended in 500 ml of cell culture medium. Cell size was estimated by passing 40 000 viable cells through the FACS analyser and measuring the forward or right angle light scatter. Data was stored as frequency histograms.
Western blotting TRAMP cells were grown on 100 mm dishes at 500 000 cells/ dish under required conditions. Whole cell extracts were prepared by washing the cells twice in PBS, then lysing cells in 250 ml 26sample buer (0.15 M Tris-HCl pH 8.8 with 40% Glycerol and 10% SDS) (Laemmei, 1970) . For Triton X-114 phasing, cells were washed twice in ice-cold PBS, and scraped into 3 ml lysing buer (10 mM Tris-HCl pH 7.5 containing 5 ml of 200 mM PMSF and 1 ml/ml of 1 mM SBTI). The cell lysates were incubated 15 min on ice with 600 ml preconditioned Triton X-114 (Sigma), and centrifuged 10 min at 10 000 g at 48C. The supernatant was phased at 378C for 4 min and further centrifuged 10 min at 3000 r.p.m. at room temperature to give an upper cytosolic (detergent depleted) and a lower membranous (detergent enriched) fraction. The two fractions were precipitated ovenight at 7208C in ethanol, after centrifugation for 10 min at 1000 r.p.m., the pellets were dried of ethanol, and dissolved in 16sample buer. Proteins were quantitated using a BCA assay (Pierce, Rockford, IL, USA) and fractionated on 14% SDS-polyacrylamide gels. Electrophoresis was performed at 45 mA for about 4 h using vertical slab units (Hoeer, San Francisco, CA, USA). The gels were electroblotted overnight at 200 mA using a Trans-Blot Cell (BioRad, Hercules, CA, USA) onto 0.2 mm PVDF membrane (BioRad Laboratories, Hercules, CA, USA). The blots were stained with monoclonal antibodies speci®c for RhoA, pan Ras or hemaglutannin (HA) (Santa Cruz Laboratories, Santa Cruz, CA, USA), which were detected by enhanced chemiluminescence (Pierce, Rockford, IL, USA) after incubation with a peroxidase labeled secondary antibody.
